Form 13-F position report

ARCTURUS THERAPEUTICS HLDGS

Reported by MORGAN STANLEY

ARCT CUSIP 03969T109 Manager CIK 0000895421

Reported 192,593 shares, up 95,187 (97.7%) from the prior quarter.

Reported value 302.8%; share count 97.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 192,593 Quarter-end amount reported
Reported value $2,636,598 Fair value at quarter end
Consecutive quarters held 30 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 5093000
2022-03-31 7548000
2022-06-30 4912000
2022-09-30 1253000
2022-12-31 2045851
2023-03-31 2818273
2023-06-30 5977398
2023-09-30 14656298
2023-12-31 18350365
2024-03-31 29327455
2024-06-30 19381164
2024-09-30 6195260
2024-12-31 9138245
2025-03-31 5842778
2025-06-30 7852783
2025-09-30 12990901
2025-12-31 1308093
2026-03-31 973763
2026-06-30 654568
2026-09-30 2636598

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ARCTURUS THERAPEUTICS HLDGS held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 192,593 +95,187 (97.7%) < 0.01% $2,636,598 2026-11-13
Q2 2026 Reduced 97,406 -28,729 (-22.8%) < 0.01% $654,568 2026-08-13
Q1 2026 Reduced 126,135 -87,257 (-40.9%) < 0.01% $973,763 2026-05-15
Q4 2025 Reduced 213,392 -491,486 (-69.7%) < 0.01% $1,308,093 2026-02-13
Q3 2025 Added 704,878 +101,282 (16.8%) < 0.01% $12,990,901 2025-11-14
Q2 2025 Added 603,596 +51,870 (9.4%) < 0.01% $7,852,783 2025-08-15
Q1 2025 Added 551,726 +13,232 (2.5%) < 0.01% $5,842,778 2025-05-15
Q4 2024 Added 538,494 +271,572 (101.7%) < 0.01% $9,138,245 2025-02-14
Q3 2024 Reduced 266,922 -529,019 (-66.5%) < 0.01% $6,195,260 2024-11-14
Q2 2024 Reduced 795,941 -72,506 (-8.3%) < 0.01% $19,381,164 2024-08-14
Q1 2024 Added 868,447 +286,450 (49.2%) < 0.01% $29,327,455 2024-05-15
Q4 2023 Added 581,997 +8,365 (1.5%) < 0.01% $18,350,365 2024-02-13
Q3 2023 Added 573,632 +365,215 (175.2%) < 0.01% $14,656,298 2023-11-15
Q2 2023 Added 208,417 +90,842 (77.3%) < 0.01% $5,977,398 2023-08-14
Q1 2023 Reduced 117,575 -3,053 (-2.5%) < 0.01% $2,818,273 2023-05-15
Q4 2022 Added 120,628 +36,110 (42.7%) < 0.01% $2,045,851 2023-02-14
Q3 2022 Reduced 84,518 -227,625 (-72.9%) < 0.01% $1,253,000 2022-11-14
Q2 2022 Added 312,143 +32,173 (11.5%) < 0.01% $4,912,000 2022-08-15
Q1 2022 Added 279,970 +142,391 (103.5%) < 0.01% $7,548,000 2022-05-13
Q4 2021 Added 137,579 +4 (0.0%) < 0.01% $5,093,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

170 managers reported ARCTURUS THERAPEUTICS HLDGS for Q3 2026.

Managers reporting ARCTURUS THERAPEUTICS HLDGS in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ARK Investment Management LLC Added 2,994,550 +92,915 0.24% $40,995,387 30 qtrs
BlackRock Inc Added 2,694,816 +80,804 < 0.01% $36,892,031 9 qtrs
Sumitomo Mitsui Trust Holdings Inc Reduced 1,689,107 -274,016 0.01% $23,123,875 30 qtrs
Nikko Asset Management Americas Inc Reduced 1,689,107 -271,351 0.29% $23,106,984 30 qtrs
FEDERATED HERMES INC Reduced 1,678,069 -1,625,571 0.03% $22,972,765 26 qtrs
TWO SIGMA INVESTMENTS LP Added 1,231,847 +140,710 0.01% $16,863,985 15 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 1,107,056 -7,900 < 0.01% $15,155,597 3 qtrs
D E Shaw & Co Inc Added 976,120 +583,762 < 0.01% $13,363,082 6 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 861,240 -90,335 < 0.01% $11,790,376 3 qtrs
JACOBS LEVY EQUITY MANAGEMENT INC Added 703,060 +55,549 0.03% $9,624,891 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
185,851
Shared
0
None
6,742

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.